You are here: Industry Insights > PD-1

News List

Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors prnasia
October 22, 2021
Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company's independently developed TIGIT monoclonal antibody (AK127)...
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China prnasia
August 06, 2021
Akeso, Inc. announced that the anti PD-1 monoclonal antibody drug Penpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited, has obtained marketing approval by the National Medical Products Administration ...
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors prnasia
July 26, 2021
Innovent Biologics, Inc. today announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors prnasia
July 16, 2021
Innovent Biologics, Inc. announced that the first patient has been dosed in a Phase 1a/1b study of IBI319, an anti-PD-1/CD137 bispecific antibody.
Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China prnasia
July 06, 2021
Innovent and Laekna today jointly announced they have entered into a collaboration agreement to evaluate the combination of Innovent's PD-1 inhibitor sintilimab and Laekna's pan-AKT kinase inhibitor afuresertib.
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China prnasia
June 15, 2021
ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June 11 2021 ...
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial europeanpharmaceuticalreview
June 08, 2021
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States prnasia
May 25, 2021
On May 24, 2021, Akeso, Inc. announced that Penpulimab, an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited, has submitted a Biologics License Application to the Food and Drug Administration of the ...
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer americanpharmaceuticalreview
April 20, 2021
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the submission of a ...
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China prnasia
March 22, 2021
Harbour BioMed (HBM) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2).

Previous page 1 2 3 4 Next page